2nd Quarter - Report
LMH STRATEGIC SOLUTIONS for GLAXOSMITHKLINE LLC
Client
Income
$40,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALANNA TEMME | Legislative Director, U.S. Representative Jon Porter |
Pharmacy PHA
Drug pricing issues. S.705 - Innovation in Pediatric Drugs Act of 2025. Issues related to the 340(b)program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.